EA
NBIX icon

Emerald Acquisition’s Neurocrine Biosciences NBIX Stock Holding History

Emerald Acquisition’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$2.15M Sell
42,419
-15,842
-27% -$789K ﹤0.01% 1709
2016
Q2 		$2.65M Buy
+58,261
New +$2.68M ﹤0.01% 1689

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Emerald Acquisition's NBIX Position: Q3 2016 in Review

Emerald Acquisition reduced its Neurocrine Biosciences (NBIX) stake by 27% in Q3 2016, selling an estimated $789K and leaving 42,419 shares worth $2.15M. The position accounts for ﹤0.01% of the portfolio, ranked #1709.

Emerald Acquisition first reported a position in NBIX in Q2 2016 and has held it in 2 quarters since. The position peaked at $2.65M in Q2 2016. 244 funds tracked by Wall St. Rank hold NBIX as of Q3 2016.

  • Emerald Acquisition held 42,419 shares of Neurocrine Biosciences worth $2.15M as of Q3 2016.
  • Emerald Acquisition sold 15,842 Neurocrine Biosciences shares in Q3 2016, an estimated $789K.
  • Neurocrine Biosciences made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #1709 holding.
  • Emerald Acquisition first reported a position in Neurocrine Biosciences in Q2 2016 and has held it in 2 quarters since.
  • Emerald Acquisition's Neurocrine Biosciences position peaked at $2.65M in Q2 2016.
  • 244 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.